The bone marrow microenvironment - Home of the leukemic blasts.
Acute Myeloid Leukaemia (AML) is a genetically, biologically and clinically heterogeneous set of diseases, which are characterised by an increased growth of abnormal myeloid progenitor cells within the bone marrow (BM). Ex-vivo AML exhibits a high level of spontaneous apoptosis. Furthermore, relapse for patients achieving remission occurs from minimal residual disease harboured within the BM microenvironment. Taken together, these observations illustrate the importance of the BM microenvironment in sustaining AML. While significant progress has been made elaborating the small-scale genetic mutations and larger-scale chromosomal translocations that contribute to the development of AML and its prognosis in response to treatment, less is understood about the complex microenvironment of the BM, which is known to be a key player in the pathogenesis of the disease. As we look towards future therapies, the consideration that the BM microenvironment is uniquely important as a niche for AML - coupled with the idea that leukaemic blasts are more likely to be genetically unstable and therefore evolve resistance to conventional chemotherapies - make the functions of the non-malignant cells of the BM attractive targets for therapy. In this review, we discuss the microanatomy of the BM and provide an overview of the evidence supporting the role of the BM microenvironment in creating conditions conducive to the survival and proliferation of AML blasts. Ultimately, we examine the therapeutic potential of uncoupling AML from the BM microenvironment.
Department of Molecular Haematology, Norwich Medical School, The University of East Anglia, Norwich Research Park, NR4 7UQ, United Kingdom.
Manar S
MS
Shafat
Norwich Medical School, The University of East Anglia, Norwich Research Park, NR4 7TJ, United Kingdom.
Bruno
B
Gnaneswaran
Department of Molecular Haematology, Norwich Medical School, The University of East Anglia, Norwich Research Park, NR4 7UQ, United Kingdom; Department of Haematology, Norfolk and Norwich University Hospitals NHS Trust, Colney Lane, Norwich NR4 7UQ, United Kingdom.
Kristian M
KM
Bowles
Department of Molecular Haematology, Norwich Medical School, The University of East Anglia, Norwich Research Park, NR4 7UQ, United Kingdom. Electronic address: s.rushworth@uea.ac.uk.
Stuart A
SA
Rushworth
D017667:Adipocytes / Q000378:metabolism; D000818:Animals; D001853:Bone Marrow / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D001854:Bone Marrow Cells / Q000378:metabolism / Q000473:pathology; D042783:Endothelial Cells / Q000378:metabolism; D005347:Fibroblasts / Q000378:metabolism; D006410:Hematopoiesis; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D059630:Mesenchymal Stem Cells / Q000378:metabolism; D058990:Molecular Targeted Therapy; D010006:Osteoblasts / Q000378:metabolism; D010010:Osteoclasts / Q000378:metabolism; D059016:Tumor Microenvironment / Q000187:drug effects
Acute myeloid leukaemia; Bone marrow; Bone marrow microenvironment